Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.05 and traded as high as $0.05. Mateon Therapeutics shares last traded at $0.05, with a volume of 26,678 shares traded.
Mateon Therapeutics Price Performance
The stock has a 50-day moving average of $0.05 and a two-hundred day moving average of $0.05.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now
- Canada Bond Market Holiday: How to Invest and Trade
- Alphabet Stock Surges After Dodging Harsh Antitrust Remedies
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Why Qualcomm Is Outperforming NVIDIA After Months of Lagging
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
